Edition:
United States

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.18USD
17 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.18
Open
$1.18
Day's High
$1.20
Day's Low
$1.18
Volume
4,317
Avg. Vol
20,842
52-wk High
$3.09
52-wk Low
$0.89

Latest Key Developments (Source: Significant Developments)

Neuralstem Appoints Jim Scully As Interim CEO
Monday, 6 Aug 2018 07:00am EDT 

Aug 6 (Reuters) - Neuralstem Inc ::NEURALSTEM APPOINTS JIM SCULLY AS INTERIM CHIEF EXECUTIVE OFFICER.NEURALSTEM - SCULLY WILL SUCCEEDS RICH DALY WHO SERVED AS PRESIDENT AND CEO OF COMPANY SINCE FEBRUARY 2016.  Full Article

Neuralstem says NSI-566 Stem Cell Therapy Confers Neurological Improvement In Spinal Cord Injury
Monday, 4 Jun 2018 07:00am EDT 

June 4 (Reuters) - Neuralstem Inc ::NEURALSTEM’S NSI-566 STEM CELL THERAPY CONFERS NEUROLOGICAL IMPROVEMENT IN SPINAL CORD INJURY PATIENTS WITH COMPLETE PARAPLEGIA.NEURALSTEM INC - ANALYSIS OF MOTOR AND SENSORY FUNCTION AND ELECTROPHYSIOLOGY RESULTS SHOWED IMPROVEMENT IN THREE OF FOUR PATIENTS.NEURALSTEM INC - ALL SUBJECTS TOLERATED PROCEDURE WELL, WITH NO SERIOUS ADVERSE EVENTS 18-27 MONTHS AFTER GRAFTING.  Full Article

Neuralstem Says At Dec. 31, 2017, Cash And Investments Was $11.7 Mln Compared To $20.2 Mln At Dec. 31, 2016
Monday, 2 Apr 2018 07:30am EDT 

April 2 (Reuters) - Neuralstem Inc ::NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE.AT DECEMBER 31, 2017, CASH AND INVESTMENTS WAS $11.7 MILLION AS COMPARED TO $20.2 MILLION AT DECEMBER 31, 2016.TERM INVESTMENTS TO FUND OPERATIONS INTO Q2 OF 2019.  Full Article

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 07:30am EST 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article

Neuralstem Inc gets two additional U.S. patents
Thursday, 7 Sep 2017 07:03am EDT 

Sept 7 (Reuters) - Neuralstem Inc :Neuralstem Inc - ‍been awarded two additional patents by United States Patent and Trademark Office​.  Full Article

Neuralstem reports Q2 loss per share $0.39
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Neuralstem Inc :Neuralstem reports second quarter 2017 fiscal results and provides clinical and business update.Q2 loss per share $0.39.  Full Article

‍CVI investments reports a 8.3 pct passive stake in Neuralstem
Monday, 7 Aug 2017 10:46am EDT 

Aug 7 (Reuters) - Neuralstem Inc :‍CVI Investments reports a 8.3 percent passive stake in Neuralstem Inc as of July 27, 2017 - SEC filing.  Full Article

Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder
Tuesday, 25 Jul 2017 08:15am EDT 

July 25 (Reuters) - Neuralstem Inc ::Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder.Neuralstem Inc - ‍study did not meet its primary efficacy endpoint​.Neuralstem Inc - 40 mg qd dose was directionally positive on madrs​.Both 40 mg QD and 40 MG bid doses of NSI-189 were well-tolerated in study with no serious adverse events reported.Neuralstem Inc - ‍results were also directionally positive on hamilton depression rating scale (ham-d17) at both doses​.Neuralstem - ‍of two secondary efficacy endpoints analyzed so far, patient-rated SDQ achieved statistical significance with NSI-189 40 MG QD​.  Full Article

Neuralstem files for mixed shelf of up to $100 mln
Thursday, 8 Jun 2017 05:11pm EDT 

June 8 (Reuters) - Neuralstem Inc ::Neuralstem Inc files for mixed shelf of up to $100 million -sec filing.  Full Article

Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder
Wednesday, 17 May 2017 04:05pm EDT 

May 17 (Reuters) - Neuralstem Inc :Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder.  Full Article

BRIEF-Neuralstem Q1 Loss Per Share $0.14

* NEURALSTEM PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FISCAL RESULTS